Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Study Summary

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Conditions

Triple Negative Breast Cancer PD-L1 Positive

Interventions / Drugs

Sacituzumab Govitecan-hziy Pembrolizumab Paclitaxel nab-Paclitaxel Gemcitabine Carboplatin

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment443 participants

Primary Completion—

Lead SponsorGilead Sciences

Data Retrieved2026-04-11 02:55:27.112639+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.